New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
08:08 EDTINFIInfinity Pharmaceuticals sees FY12 revenue $47.1M, consensus $113.91M
Infinity expects FY12 total revenue $47.1M composed of $45.0M for reimbursed R&D services from Mundipharma and $2.1M due to the amortization of deferred revenue. Infinity does not expect to recognize any revenue in future periods from the previous strategic alliance with Purdue and Mundipharma. Infinity expects FY12 operating expenses $125M-$135M revised from an earlier expectation of $135M-$145M. Infinity expects FY12 net loss $35M-$45M. Cash and investments: Infinity expects to end 2012 with a year-end cash and investments balance ranging from $155M-$165M, revised from an earlier expectation of $65M-$75M.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
16:04 EDTINFIInfinity Pharmaceuticals reports Q4 EPS (83c), consensus (98c)
Reports Q4 revenue $4.36M, consensus $5.61M. Completion of patient enrollment in DYNAMO and DUO trials expected in 2015, topline data from DYNAMO is anticipated in the second half of 2015 and three new clinical studies of Duvelisib are expected to begin in 2015, the company said. At December 31, 2014, Infinity had total cash, cash equivalents and available-for-sale securities of $333.2M, compared to $214.5M at December 31, 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use